Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Ordinary Shares, $0.0001 par value
-
Shares outstanding
-
53,512,954,839
-
Total 13F shares
-
304,298
-
Share change
-
-18,485
-
Total reported value
-
$377,330
-
Price per share
-
$1.24
-
Number of holders
-
10
-
Value change
-
-$22,653
-
Number of sells
-
5
Institutional Holders of Akari Therapeutics Plc - Ordinary Shares, $0.0001 par value (AKTX) as of Q1 2025
As of 31 Mar 2025,
Akari Therapeutics Plc - Ordinary Shares, $0.0001 par value (AKTX) was held by
10 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
304,298 shares.
The largest 10 holders included
Palo Alto Investors LP, Omnia Family Wealth, LLC, Cerity Partners LLC, Cresset Asset Management, LLC, RENAISSANCE TECHNOLOGIES LLC, Accent Capital Management, LLC, BANK OF AMERICA CORP /DE/, Truvestments Capital LLC, MORGAN STANLEY, and Cornerstone Planning Group LLC.
This page lists
10
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.